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OBJECTIVES: To present nationally representative estimates of the impact of 
cancer survivorship on medical expenditures and lost productivity among adults 
in the United States. METHODS: Using the 2008-2010 Medical Expenditure Panel 
Survey we identified 4,960 cancer survivors and 64,431 individuals without a 
history of cancer aged ≥18 years. Direct medical costs were measured using 
annual health care expenditures and examined by source of payment and 
service type. Indirect morbidity costs were estimated from the lost productivity 
due to health-related unemployment, missed work days, and lost household 
productivity. We evaluated the economic burden of cancer survivorship by 
estimating the excess costs among cancer survivors compared with individuals 
without a history of cancer using multivariable regression models stratified by 
age (18-64 and ≥65 years) while controlling for age, gender, education, and 
comorbidities. RESULTS: In 2008-2010, the annual excess economic burden of 
cancer survivorship was $7,631 per cancer survivor aged 18-64 years and $5,445 
per survivor aged ≥65 years. Excess direct medical expenditures comprised the 
largest share, with excess annual medical expenditures of $5,570 and $4,683 
among cancer survivors aged 18-64 years and ≥65 years, respectively. 
Ambulatory care accounted for the largest share of medical expenditures in both 
groups. The largest source of payment was private health insurance for cancer 
survivors aged 18-64 years, and Medicare for cancer survivors aged ≥65 years. 
Cancer survivors aged 18-64 years incurred an excess annual productivity loss of 
$2,061 per individual while cancer survivors aged ≥65 years reported an excess 
annual lost productivity of $762 per individual. CONCLUSIONS: The economic 
burden of cancer survivorship is substantial, resulting in excess health care 
expenditures and lost productivity costs compared with individuals without a 
history of cancer. Efforts to reduce the economic burden caused by cancer will be 
increasingly important given the growing population of cancer survivors.  
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OBJECTIVES: To estimate the incremental health care costs associated with 
adverse events (AEs) among metastatic melanoma (MM) patients treated with 
seven commonly used therapies. METHODS: Retrospective health care claims 
from the Marketscan® commercial and Medicare supplemental databases were 
examined from June 1, 2004 to April 30, 2012. Patients included those ≥18 years 
who had diagnosed melanoma (ICD-9 code: 172.xx) with at least one diagnosis of 
metastasis within 30 days prior to or 60 days after any melanoma diagnosis, and 
≥ one claim for any of the following MM treatments: paclitaxel, vemurafenib, 
ipilimumab, dacarbazine, temozolomide, high dose interleukin-2, or interferon 
alpha. AE categories of interest included cardiovascular, CNS/psychiatric, 
metabolic disorders, gastrointestinal, hemic/lymphatic disorders, pain, and 
skin/subcutaneous events that occurred after initiation of therapy. Health care 
encounters for AEs were based on ICD-9-CM diagnosis/procedure codes on 
health care claims. The incremental cost per AE was determined by comparing 
the 30-day expenditures in patients with the event to patients without the event 
based on a 30-day shadow event date. Drug costs of the MM therapies were 
excluded from the analysis. Multivariate generalized linear models (GLM) with a 
log-link function and gamma distribution were utilized to control for differences 
in baseline characteristics between groups. RESULTS: A totla of 2621 MM 
patients were included in this analysis. Mean age was 56.0 years (SD: 13.0), 64% 
were male and 24% had a diagnosis of primary or secondary brain cancer at the 
time of MM diagnosis. The GLM-based estimate of 30-day incremental costs by 
AE category were: metabolic, $9,135 (95% CI: $6,404-$12,392); hemic/lymphatic, 
$8,450 ($6,528-$10,633); cardiovascular, $6,476 ($4,667-$8,541); gastrointestinal, 
$6,338 ($4,740-$8,122); skin/subcutaneous, -$900 (-$1,899- $237); CNS/psychiatric, 
$5,903 ($3,842-8,313); and pain, $5,078 ($3,392-$7,012). CONCLUSIONS: The 
incremental costs associated with AEs therapies to treat MM are substantial. 
New approaches to prevent and/or better manage these events may reduce 
overall health care costs.  
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OBJECTIVES: To characterize real-world medical resource utilization and costs 
following initiation of anti-cancer treatments for patients with Stage IB-IV Non-
Small Cell Lung Cancer (NSCLC). METHODS: A retrospective, longitudinal, open-
cohort study design was chosen using Medicare linked Surveillance 
Epidemiology and End Results (SEER) data. All Medicare-eligible patients in the 
SEER registry who were diagnosed with NSCLC during 2005–2007 and treated 
with anti-cancer therapy were identified. The observation period spanned from 
NSCLC diagnosis through the earliest date of end of anti-cancer therapy, data 
end date, or death. All-cause and NSCLC-related utilization and costs were 
reported, stratified by hospitalization, emergency room (ER), and outpatient 
visits. Results were stratified by patients with non-advanced cancer (Stages IB-
IIIA) and advanced cancer (Stages IIIB-IV). Pharmacy costs were reported for 
patients diagnosed with NSCLC in 2007. RESULTS: The study population 
consisted of 6,365 patients; mean (SD) age was 73.7 (5.4) years, 54% were males, 
and median follow-up was 351 days. The all-cause rate per patient per month 
(PPPM) was 0.14, 0.10, and 4.08; NSCLC-related PPPM rate was 0.12, 0.05, and 2.86 
for hospitalization, ER, and outpatient, respectively. The median monthly length 
of stay (days) for hospitalization was 1.25 for all-cause and 1.0 for NSCLC-related 
stays. The mean all-cause PPPM costs were $4,989 (hospitalization: $2,278, ER: 
$54, outpatient: $2,657). The mean NSCLC-related PPPM costs were $4,032 
(hospitalization: $1,721, ER: $23, outpatient: $2,288). The mean all-cause PPPM 
costs were $3,805 ($2,873 NSCLC-related) for patients with non-advanced cancer 
and $5,822 ($4,847 NSCLC-related) for patients with advanced cancer. All-cause 
PPPM prescription drug costs were $560. CONCLUSIONS: The SEER-Medicare 
database analysis found that in Stage IB-IV NSCLC patients, NSCLC-related costs 
accounted for over 80% of all health care costs while patients were on anti-
cancer therapies. Higher costs were incurred by patients diagnosed with 
advanced NSCLC as compared to patients diagnosed with non-advanced disease.  
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OBJECTIVES: Despite major advances, resistance and intolerance continue to be 
a significant challenge in the management of CML. This study evaluated the real-
world resource use and costs associated with CML treatment failure with 
dasatinib or nilotinib (defined as treatment switch or discontinuation) from a US 
payer perspective. METHODS: This was a retrospective study using the IMS 
PharMetrics health plan claims database from July 2006-June 2011. Adult patients 
with CML diagnosis (ICD-9 205.1x) with ≥1 fill of dasatinib or nilotinib were 
selected. Failure was defined as a switch to another tyrosine kinase inhibitor 
(TKI) or a gap in index TKI >90 days. Direct medical resource use and costs (2011 
USD) were measured for those with 6 months of continuous enrollment post-
failure, including all-cause medical and pharmacy costs. RESULTS: 608 CML 
patients were identified initiating dasatinib or nilotinib, of which 290 
experienced treatment failure. Of these, 192 had 6 months of continuous 
enrollment post-failure. Average age was 57.5 years and 55.7% were female. 
Mean 6-month costs post-failure were $79,996 (median $33,100), with inpatient 
costs comprising 54.4%, followed by pharmacy (23.1%) and outpatient (22.2%). 
During the 6 months post-failure, one-third of patients had at least one 
hospitalization (median 12 days) with leukemia being the most frequent primary 
diagnosis for hospitalization, 22% had an emergency room visit, 96% had 
physician office visits (median 11 visits), with a median of 27 lab tests and 20 
prescription fills per person (median 16 non-TKI fills). CONCLUSIONS: The 6-
month economic burden of failure from nilotinib and dasatinib is substantial and 
is largely due to the disease. The availability of new agents to effectively manage 
this hard-to-treat population has the potential to improve costs of care by 
preventing disease progression.  
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OBJECTIVES: To determine the usage and costs of oral cancer treatment in 
elderly Medicare Part D beneficiaries. METHODS: A cross-sectional retrospective 
study was conducted using a 5% random sample of 2008 Medicare beneficiaries. 
The study sample included all members of this group who: 1) were 65 years of 
age and older and 2) filled at least one prescription for imatinib, erlotinib, 
anastrozole, letrozole, or thalidomide.We examined the average costs patients 
paid per day, the cost that the Part D plan paid per day, and total cost for the 
entire year for each drug. We determined the percentage of enrollees who 
entered the Part D coverage gap, the time, and duration that they fell into the 
coverage gap. RESULTS: Prescription drug subsidy was categorized in four 
groups: 1) Dual Eligible (DE); 2) full Low Income Subsidy (LIS); 3) partial LIS; and 4) 
no subsidy. Mean out-of-pocket (OOP) costs per day were between $0.03 and 
$0.09 for DE beneficiaries, between $0.04 and $0.22 for full LIS beneficiaries, 
between $1.17 and $6.34 for partial LIS beneficiaries,and between $2.92 and 
$36.83 for beneficiaries who did not receive a subsidy. About 99% of users of the 
more expensive drugs - imatinib, erlotinib and thalidomide - entered the 
coverage gap and the majority of these entered the coverage gap at the time of 
their first fill. In contrast, beneficiaries who filled the less expensive drugs - 
anastrozole and letrozole- entered the coverage gap later. Beneficiaries who used 
imatinib, erlotinib, or thalidomide spent approximately a month in the coverage 
gap. The majority of their time was spent in the catastrophic phase. 
CONCLUSIONS: Beneficiaries receiving subsidies had low OOP costs, averaging 
between $0.03 and $6.34 per day. Beneficiaries on the more expensive drugs and 
not having subsidies had high OOP costs, averaging between $15.66 and 36.83 per 
day.  
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OBJECTIVES: The rising costs of cancer care are a major focus for clinicians, 
payers and patients. This analysis describes changes in location of 
chemotherapy administration and reimbursement, highlighting areas for 
potential policy changes METHODS: Using the MarketScan©Research Databases, 
administrations of bevacizumab and trastuzumab were identified from January 
